Process for crystallizing a 4-azasteroid 5alpha-reductase inhibitor
    1.
    发明授权
    Process for crystallizing a 4-azasteroid 5alpha-reductase inhibitor 失效
    结晶4-azasteroid5α-还原酶抑制剂的方法

    公开(公告)号:US5585383A

    公开(公告)日:1996-12-17

    申请号:US434082

    申请日:1995-05-03

    IPC分类号: C07J73/00 C07S73/00 A61K31/58

    CPC分类号: C07J73/005

    摘要: By this invention, there is provided a process for producing crystalline 4,7.beta.-dimethyl-4-aza-5.alpha.-cholestan-3-one of structural formula (I) from 4,7.beta.-dimethyl-4-aza-5.alpha.-cholestan-3-one oil. ##STR1## This crystallization process of the present invention comprises crystallization of the oil optionally containing residual solvent with vigorous but controlled agitation. Preferably, this crystallization process is carried out at select and controlled temperatures. Further, 4,7.beta.-dimethyl-4-aza-5.alpha.-cholestan-3-one has been found to exist in at least two novel polymorphic nonsolvated forms, herein referred to as Form I and Form II. Form I can be prepared pure by careful control of the crystallization process.

    摘要翻译: 通过本发明,提供了一种从4,7β-二甲基-4-氮杂-5(5)的结构式(I)生产结晶4,7β-二甲基-4-氮杂-5α-胆甾烷-3-酮的方法, α-胆甾烷-3-酮油。 (I)本发明的结晶方法包括在剧烈而受控的搅拌下任选地含有残留溶剂的油的结晶。 优选地,该结晶过程在选择和控制的温度下进行。 此外,已经发现4,7β-二甲基-4-氮杂-5α-胆甾烷-3-酮存在于至少两种新型多态性非相溶形式中,本文称为I型和II型。 形式I可以通过仔细控制结晶过程来制备纯。